False Results Possible With Curative SARS-CoV-2 Test, Says FDA
The test should be utilized in accordance with its Emergency Use Authorization and as described in the authorized labeling to reduce the risk of false negative results.
Viral Infections
Counterfeit HIV Drug Identified in Three US Pharmacies
The counterfeit products were procured from unauthorized distributors.
Risk for Death, Complications Higher With COVID-19 Versus Flu
Risk for mechanical ventilation use, admission to intensive care, longer length of stay increased for COVID-19 versus flu
Ebola Virus Treatment Ebanga Gets FDA Approval
Ebanga is a human IgG1 monoclonal antibody designed to block the binding of the virus to the cell receptor, preventing its entry into the cell.
ACAAI: Reaction to COVID-19 Vaccine Unlikely for Those With Common Allergies
Pfizer COVID-19 vaccine should not be administered to individuals with a known history of severe reaction to polyethylene glycol
Moderna’s COVID-19 Vaccine Gets EUA; Shipping Begins
The EUA was based on data from the placebo-controlled COVE study that investigated the efficacy and safety of mRNA-1273 in more than 30,000 adults aged 18 years and older.
FDA Panel Recommends EUA for Moderna’s COVID-19 Vaccine
The EUA recommendation was based on data from the placebo-controlled COVE study that investigated the efficacy and safety of mRNA-1273 in more than 30,000 adults aged 18 years and older.
MPR Weekly Dose Podcast Episode 62
Its been a long year, but the monumental efforts to achieve a COVID-19 vaccine are bearing some fruits, we about that, and also a fully at home diagnostic COVID test, as well as new findings related to glucosamine supplements and a novel treatment for eosinophilic esophagitis. And as ever, one final movie trivia ‘guess the quote’ to end the year!
FDA Authorizes First OTC Rapid Antigen Test for COVID-19
The Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to Ellume COVID-19 Home Test, the first over-the-counter (OTC) fully at-home diagnostic antigen test for coronavirus disease 2019 (COVID-19). The Ellume COVID-19 Home Test is a rapid, lateral flow antigen test developed with support from the National Institutes of Health’s Rapid Acceleration of…
No Benefit With Ruxolitinib for COVID-19 Associated Cytokine Storm
The global, double-blind, placebo-controlled RUXCOVID study compared ruxolitinib to placebo, in addition to standard of care, in 432 patients aged 12 years and older with COVID-19 associated cytokine storm.
